A review of socio-behavioural studies on adherence to antiretroviral treatments: Beyond biomedical models?;Un bilan des recherches socio-comportementales sur l'observance des traitements dans l'infection a VIH: Au dela des modeles biomedicaux?

Revue d'Epidemiologie et de Sante Publique

Volumn 48, Issue 2, 2000, Pages 182-197

  Moatti, J P ^a,b   Spire, B ^a   Duran, S ^a  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Adherence; Compliance; HAART; HIV; Multiple therapy

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; DAILY LIFE ACTIVITY; DIFFUSION; HORMONE SUBSTITUTION; PATIENT COMPLIANCE; PREDICTION; RETROVIRUS; REVIEW; TREATMENT PLANNING;

ANTI-HIV AGENTS; ATTITUDE TO HEALTH; FORECASTING; HEALTH BEHAVIOR; HEALTH STATUS; HIV INFECTIONS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PUBLIC HEALTH; SELF ADMINISTRATION; SELF CARE; SELF CONCEPT; SOCIAL ADJUSTMENT;

EID: 0033935976     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Dunbar J. Predictors of patient adherence: patient characteristics. In. Shumaker S ed. New-York: The handbook of health behavior change. Springer Pub Co, 1990.
2. Janz N, Becker M. The health belief model: a decade later. Health Educ Q 1984; 11: 1-47.
3. Arrow KJ. Uncertainty and the welfare economics of medical care. Am Eco Rev 1963; 53: 941-73.
4. Rochaix L. L'analyse du marché des soins médicaux: quelle place pour l'économie de la santé? Rev Epidemiol Sante Publique 1996; 44: 498-510.
5. Laplantine F. Anthropologie de la maladie. 2nd éd. Paris: Payot, 1992.
6. e édition), 1991.
7. Bayer R. Public health policy and the AIDS epidemic. An end to HIV exceptionalism? JAMA 1991; 3: 1500-4.
8. Haynes R, McKibbon K, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow presctriptions for medications. Lancet 1996; 100: 258-68.
9. Miller N. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 17: 43-9.
10. Myers L, Midence K. Adherence to treatment in medical conditions. The Netherlands: Harwood Academic Publ, 1998.
11. Ley P. Communicating with patients. London: Croom Helm, 1988.
12. Katz M, Bindman A, Komaromy M. Coping with HIV infection: why people delay care? Ann Intern Med 1992; 117: 797-800.
13. Leventhal H, Safer M, Panagis D. The impact of communications on the self-regulation of health beliefs, decisions, and behavior. Health Educ Q 1983; 10: 3-29.
14. Aïach P, Cèbe D. Expression des sympômes et conduites de maladie. Paris: INSERM/Doin, 1991.
15. Tessler R, Mechanic D, Dimond M. The effect of psychological distress on physician utilization: A prospective study. Health Soc Behav 1976; 17: 353-64.
16. Kissinger P, Cohen D, Brandon W, Rice J, Morse ARC. Compliance with public sector HIV medical care. J Natl Med Assoc 1995; 87: 19-24.
17. Chesney M. Health psychology in the 21st century: AIDS as a harbinger of things to come. Health Psychol 1993; 12: 259-68.
18. Chesney M, Folkman S. Psychological impact of HIV disease and implications for intervention. Psych Clin North America 1994; 12: 259-68.
19. Munzenberger N, Cassuto J, Gastaut J, Souville M, Morin M, Moatti J. Observance dans les essais cliniques de l'infection à VIH. Presse Medicale 1997; 26: 358-65.
20. Dormont J. (ed) Stratégies d'utilisation des antirétroviraux dans l'infection à VIH. Secrétariat d'État à la Santé Médecine Sciences. Paris: Flammarion, 1998.
21. Decks S, Smith M, Holodniy M, Kahn J. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145-53.
22. McDonald C, Kuritzes D. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997; 157: 951-9.
23. Carpenter C, Fischl M, Hammer S et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 278: 1234-5.
24. Carpenter CC, Fischl M, Hammer S, Hirsch MS, Jacobsen DM, Katzenstein DA et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280: 78-86.
25. Department of Health and Human Services. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. (DHHS). Washington D.C.: 1998.
26. Dulioust A, Paulous S, Guillemot L, Delavalle A, Boue F, Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease. J Virol 1999; 73: 850-4.
27. Vandamme A, Van Vaerenbergh K, De Clercq E. Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 1998; 9: 187-203.
28. Ickovics J, Meisler A. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 1997; 50: 385-91.
29. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaut JA et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998; 339: 1269-76.
30. Moutouh L, Corbeil J, Richman D. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci USA 1996; 93: 6106-11.
31. Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279: 1977-83.
32. Edlin BR, Tokars JL, Grieco MH, Crawford JT, Williams J, Sordillo EM et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 1514-21.
33. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339: 307-11.
34. Senak M. Predicting antiviral compliance: physician's responsibilities vs. patients' rights. J Intl Assn Phys in AIDS Care 1997; 3: 45-8.
35. Stewart G. Adherence to antiretroviral therapies. In: Van Praag E, Fernyak S, Katz A, eds. The implications of antiretroviral treatments. Informal consultation. Geneva: WHO/UNAIDS, 1997; 35-50.
36. Pollak M, Dab W, Moatti J-P. Systèmes de réaction au SIDA et action préventive. Sciences Sociales & Santé 1989; 7: 111-35.
37. Emanuel E. Do physicians have an obligation to treat patients with AIDS? N Engl J Med 1998; 318: 1686-90.
38. Kirp D, Bayer R. AIDS in the industrialized democracies. Passions, politics and policies. New Brunswick, NJ: Rutgers University Press, 1992.
39. Foucault M. Surveiller et punir: naissance de la prison. Paris: Gallimard, 1975.
40. Fischoff B. "Acceptable risk": the case of nuclear power. J Pol Anal & Management 1983; 2: 559-75.
41. Mehta S, Moore R, Graham N. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665-70.
42. Coons S, Sheahan S, Martin S, Hendricks J, Robbins C, Johnson J. Predictors of medical non-compliance in a sample of older adults. Clin Therapeut 1994; 16: 110-7.
43. Hughues W, Rivera G, Schell M, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocysitis Cariniii pneumonitis. N Engl J Med 1987; 316: 1627-32.
44. Ruskin J, Lariviere M. Low-dose cotrimoxazole for prevention of Pneumocysitis Carinii pneumonia in human immunodeficiency virus disease. Lancet 1991; 337: 468-71.
45. Hal DB, Montaner JG, Reiss P, Cooper D, Vella S, Dohnanyi C et al. Induction-maintenance antiretroviral therapy: proof of concept. AIDS 1998; 12: F41-4.
46. Hecht F, Colfax G, Swanson M, Chesney M. Adherence and effectiveness of protease inhibitors in clinical practice. 5th Conference on Retroviruses and Opportunistic Infections: Chicago Feb 2-Feb 6, 1998.
47. Paterson D, Swindells S, Mohr J et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. 6th Conference on Retroviruses and Opportunistic Infections: (Abstract 92), Chicago Jan 31 -Feb 4, 1999.
48. Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
49. Miller L, Liu L, Beck K et al. Provider's estimates of adherence overestimates reports from medication event monitoring system (MEMS) for patients on protease inhibitors (PIs). 6th conference on retrovirus and opportunistic infections: (Abstract 97), Chicago Jan 31-Feb 4, 1999.
50. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, von Overbeck J, Leduc D et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with HIV infection treated with ritonavir plus saquinavir. AIDS 1997; 11: F95-F99.
51. Perello L, Goujard C, Delfraissy J, Taburet A. Therapeutic drug monitoring in HIV-infected patients receiving indinavir. 12th International AIDS Conference: (Abstract No 42772), Geneva, Switzerland Jun 28-Jul 3, 1998.
52. Peytavin G, Farinotti R. in French: Protease inhibitors daily dosage adaptation by measuring drug plasmatic concentration. Pyrexie 1998; 2: 269-77.
53. Golin C, Liu H, Hays R et al. Self-reported adherence to protease inhibitors substantially overestimates an objective measure. 6th conference on retrovirus and opportunistic infections: (Abstract 95), Chicago Jan 31-Feb 4, 1999.
54. Brooks G, Richards J, Kohler C, Soong S. Assessing adherence to asthma medication and inhaler regimens: a psychometric analysis of adult self-report scales. Med Care 1996; 32: 298-307.
55. Nieukwerk P, Gisolf E, Leewen V, Danner S, De Boer J, Sprangers M. Self-report adherence to ritonavir/saquinavir and ritonavir/saquinavir/stavudine in a randomized clinical trial: preliminary results. 12th International AIDS Conference: (Abstract No 32362), Geneva, Switzerland Jun 28-Jul 3, 1998.
56. Weidle P, Ganea C, Ernst J. Multiple reasons for non-adherence to antiretroviral medications in an inner city minority population: need for multifacted approach. 12th International AIDS Conference: (Abstract No 32360), Geneva, Switzerland Jun 28-Jul 3, 1998.
57. Bangsberg D, Hecht F, Charlebois E et al. Spontaneous adherence audits predict viral suppression in the REACH cohort. 6th Conference on Retroviruses and Opportunistic Infections: (Abstract 93), Chicago Jan 31-Feb 4, 1999.
58. Demasi R, Tolson J. Pham S et al. Self-reported adherence to HAART and correlation with HIV RNA: initial results with the patient medication adherence questionnaire. 6th Conference on Retroviruses and Opportunistic Infections: (Abstract 94), Chicago Jan 31-Feb 4, 1999.
59. Sackett D, Haynes R, Gibson E, Hackett BC, Taylor W, Roberts RS et al. Randomised clinical trial of strategies for improving medical compliance in primary hypertension. Lancet 1975; 1: 1205-7.
60. Pablos-Mendez A, Knirsch C, Barr R, Lerner B, Frieden T. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102: 164-70.
61. Muma R, Ross M, Parcel G, Pollard R. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995; 7: 439-47.
62. Singh N, Squier C, Sivek C, Wagener M, Nguyen M, Yu V. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8: 261-9.
63. Chesney M, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 1999 (in press).
64. Souville M, Leport C, Raffi F et al. Factors associated with short-term adherence to Protease Inhibitors therapy in a French cohort. 4th International Conference on AIDS Impact: Biopsychosocial Aspects of HIV infection: Ottawa, Canada July 15-18, 1999.
65. Carr A, Samaras K, Chisholm D, Cooper D. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-3.
66. Carr A, Cooper D. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998; 339: 1296.
67. Souville M, Leport C, Raffi F et al. Short-term HAART associated factors to compliance in an adult HIV-infected individuals cohort. Deuxième Séminaire ANRS de Recherche Clinique: (Abstract No A68), Paris Dec 10-11, 1998.
68. Nakashima A, Jones J, Burgess D, Ward J. Adherence to currently prescribed antiretroviral therapies: results from a multisite interview project. 12th International AIDS Conference: (Abstract No 32326), Geneva, Switzerland Jun 28-Jul 3, 1998.
69. Gifford A, Shively M, Bormann J, Timberlake D, Bozzette S. Self-reported adherence to combination antiretroviral medication (ARV) regimens in a community-based sample of HIV-infected adults. 12th International AIDS Conference: (Abstract No 32338), Geneva, Switzerland Jun 28-Jul 3, 1998.
70. Ohmit S, Schuman P, Schoenbaum E et al. Adherence to antiretroviral therapy (ART) among women in the HIV epidemiology research study (HERS) and women's inter-agency HIV study (WIHS). 12th International AIDS Conference: (Abstract No 32347), Geneva, Switzerland Jun 28-Jul 3, 1998.
71. Lorenzen T, Stoehr A, Weitner L, Adam A, Jarke J, Plettenberg A. Compliance with antiretroviral multidrug therapy in HIV-infected patients and reasons for non-compliance. 12th International AIDS Conference: (Abstract No 32371), Geneva, Switzerland Jun 28-Jul 3, 1998.
72. Heinäsmäki T, Shi Q, Creagh T et al. Adherence and antiretroviral responses to highly active antiretroviral therapy (HAART) in patients infected with Human immunodeficiency virus (HIV): comparison between an outpatient clinic and a clinical trials unit. 12th International AIDS Conference: (Abstract No 32380), Geneva, Switzerland Jun 28-Jul 3, 1998.
73. Johnston B, Ahmad K, Smith C, Rose D. Adherence to highly active antiretroviral therapy among HIV-infected patients of the inner city. 12th International AIDS Conference: (Abstract No 32389), Geneva, Switzerland Jun 28-Jul 3, 1998.
74. d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12: 1631-7.
75. Trostle J. Medical compliance as an ideology. Soc Sci Med 1988; 27: 1299-308.
76. Ironson G, Friedman A, Klimas N et al. Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with HIV. Intl J Behav Med 1994; 1: 90-105.
77. Gruffaz-Mauris M. Furthering compliance with triple antiretroviral therapy: a common worshop between patients and a ward staff. 12th international conference on AIDS: (Abstract 32340), Geneva, Switzerland Jun 28-Jul 3, 1998.
78. Le Coz S, Rébillon M, Tourette-Turgis C, Bithoun J, Burnel T, Doazan J. Counseling PWAs on adherence issues. 12th international conference on AIDS: (Abstract 24330), Geneva, Switzerland Jun 28-Jul 3, 1998.
79. Chesney M, Folkman S, Chambers D. Coping effectiveness training for men living with HIV: preliminary findings. Int J STD AIDS 1996; 7: 75-82.
80. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. AIDS Care 1997; 8: 43-54.
81. Norell S. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med 1981; 15: 57-61.
82. Eldred L, Wu A, Chaisson R, Moore R. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr 1998; 18: 117-25.
83. Vicentini R, Fossati A, Bagnato M et al. Compliance to treatment and its relationship with personality disorders in HIV-positive patients. 2nd European Conference on the Methods and Results of Social and Behavioural Sciences: AIDS in Europe: Paris, Jan, 1998.
84. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154: 1121-7.
85. Morin M, Obadia Y, Moatti J. Groupe Sida-MG (Marseille). La médecine générale face au Sida. Paris: INSERM, 1997.
86. Barbour R. The Impact of Working with people with HIV/AIDS: a Review of the Literature. Soc Sci Med 1994; 39: 221-32.
87. Horsman J, Sheeran P. Health Care Workers and HIV/AIDS: A Critical Review of the Literature. Soc Sci Med 1995; 41: 1535-67.
88. Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res 1995; 30: 593-614.
89. Tramarin A, Campostrini S, Tolley K, De Lalla F. The influence of socio-economic status on health service utilisation by patients with AIDS in North Italy. Soc Sci Med 1997; 45: 859-66.
90. Hu D, Byers JP, Fleming P, Ward J. Characteristics of persons with late AIDS diagnosis in the United States. Am J Prev Med 1995; 11: 114-9.
91. Carrieri P, Moatti JP, Vlahov D et al. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. J Epidemiol Community Health 1999; 53: 4-8.
92. Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners' attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction 1998; 93: 1567-75.
93. Celentano D, Vlahov D, Cohn S, Shadle V, Obasanjo O, Moore R. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280: 544-6.
94. Strathdee S, Palepu A, Cornelisse P, Yip B, O'Shaughnessy MV, Montaner JS et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-9.
95. Bonuck K, Arno P. Social and medical factors affecting hospital discharge of persons with HIV/AIDS. J Epidemiol Community Hlth 1997; 22: 225-32.
96. Boudon R, Bouvier A, Chazel F. Cognition et sciences sociales. Paris: PUF, 1997.
97. Stimson G, Des Jarlais D, Ball A. Drug injecting and HIV infection. London: WHO & UCL Press, 1998.
98. Freeman R, Rodriguez G, French J. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev 1996; 8: 58-71.
99. Sorensen J, Mascovich A, Wall T, DePhilippis D, Batki S, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 1998; 10: 297-312.
100. Chaisson R, Keruly J, Moore R. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333: 751-6.
101. Gourevitch M, Wasserman W, Panero M, Selwyn P. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996; 15: 93-104.
102. Wall T, Sorensen J, Batki S, Delucchi K, London J, Chesney M. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995; 37; 261-9.
103. Lerner B, Gulick R, Dubler N. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998; 129: 573-8.
104. Ajzen I, Fishbein M. Understanding attitudes and predicting social behavior. Englewood Cliffs, New Jersey: Prentice Hall, 1980.
105. Becker M. Patient adherence to prescribed therapies. Med Care 1985; 23: 539-55.
106. Bandura A. Social foundations of thought and action: A social cognitive theory. Englewood Cliffs, New Jersey: Prentice Hall, 1986.
107. Moatti J, Beltzer N, Dab W. Les modèles d'analyse des comportements à risque face à l'infection à VIH: une conception trop étroite de la rationalité. Population 1993; 5: 1505-34.
108. National Research Council. Improving risk communication. Washington DC, USA: National Academy Press, 1989.
109. Fischhoff B, Lichtenstein S, Slovic P, Derby S, Keeney R. Acceptable risk. New-York: Cambridge University Press, 1981.
110. Cassou B, Schiff M. Qui décide de notre santé? Les citoyens face aux experts. Paris: Syros, 1998.
111. Picavet E. Choix rationnel et vie publique. Paris: PUF, 1996.
112. Hitckock P, Obantley P, Jones G, Mc Knignt G. Stress and social support as predictors of dietary compliance in hemodialysis patients. Beh Med 1992; 18: 13-20.
113. Fischer J. Possible effects of reference group-based social influence on AIDS-risk behavior and AIDS prevention. Amer Psy 1988; 43: 914-20.
114. Doise W, Palmonari A. L'étude des représentations sociales. Neuchâtel/Paris: Delachaux et Nestlé, 1986.
115. Radley A, Billig M. Accounts of health and illness: Dillemmas and representations. Sociol Hlth & Ill 1996; 18: 220-40.
116. Corbin J, Strauss A. Managing chronic illness at home: three lines of work. Qual Sociol 1986; 8: 224-47.
117. Bury C. Chronic illness as biographical disruption. Sociol Hlth & Ill 1982; 4: 167-82.
118. Weitz R. Uncertainty and the lives of persons with AIDS. J Hlth Soc Behav 1989; 30: 111-22.
119. Pierret J. Coping with AIDS in everyday life. Current Sociol 1991; 40: 66-84.
120. Carricaburu D, Pierret J. Vivre au quotidien en étant séropositif asymptomatique: une enquête auprès d'hommes hémophiles et homosexuels. In: Pierret J, Bungener M, Duroussy M, Souteyrand Y, eds. Les personnes atteintes: des recherches sur leur vie quotidienne et sociale. Paris: ANRS, Sciences Sociales, 1994.
121. Voelker R. Debating dual AIDS guidelines. JAMA 1997; 278: 613.
122. Landman R, Kertenian I, Perrin V, Huard P, Moatti JP. Incertitudes scientifiques et variabilité des attitudes thérapeutiques dans l'infection à VIH. Presse Médicale 1999; 28: 899-907.
123. Jones LJ. The social context of health and health work. MacMillan Press Ltd, London, 1994.
124. Morse E, Simon P, Coburg M, Hyssop N, Greenspan D, Balson P. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991; 32: 1161-7.
125. Smith M, Rapkin B, Morrison A, Kammerman S. Zidovudine adherence in persons with AIDS: the relationship of patients beliefs about medication to self-termination of therapy. J Gen Intern Med 1997; 12: 216-23.
126. Knobel H, Carmona A, Grau S, Sabalis P, Gimeno JL, Lopez-Colomes JL. Strategies to optimise adherence to highly active antiretroviral treatment. Abstract 32322, 12th World AIDS Conference, Geneva, June 28/July 3, 1998.
127. Ohmit S, Schuman P, Schoenbaum E et al. Adherence to antiretroviral therapy (ART) among women in the HIV Epidemiology Research Study (HERS) and Women's Inter-Agency HIV Study (WIHS). Abstract 32347, 12th World AIDS Conference, Geneva, June 28/July 3, 1998.
128. Weidle PJ, Ganea CE, Ernst J, Mc Gowan J, Irwin KL, Holberg SD. Multiple reasons for nonadherence to antiretroviral medications in an inner-city minority population: need for a multifaceted approach to improve adherence. Abstract 32360, 12th World AIDS Conference, Geneva, June 28/July 3, 1998.